McKesson Stock Price Target and Analyst Ratings (NYSE:MCK)

Analyst Price Target for MCK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$191.33

▲ +9.26% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for McKesson in the last 3 months. The average price target is $191.33, with a high forecast of $231.00 and a low forecast of $165.00. The average price target represents a 9.26% upside from the last price of $175.11.

Buy

The current consensus among 12 investment analysts is to buy stock in McKesson. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

9/14/2019

0 strong buy ratings
8 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/13/2019

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/12/2020

1 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/10/2020

1 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/8/2020

1 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/7/2020

1 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/5/2021

1 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/7/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/2/2021	Cowen	Boost Price Target	Positive ➝ Outperform	$210.00 ➝ $224.00	Low	i
2/3/2021	Morgan Stanley	Boost Price Target	Overweight	$219.00 ➝ $226.00	Low	i
2/3/2021	Credit Suisse Group	Boost Price Target	Neutral	$178.00 ➝ $192.00	Low	i
2/3/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$222.00 ➝ $231.00	Low	i
2/3/2021	Mizuho	Boost Price Target	Neutral	$178.00 ➝ $190.00	Low	i
2/1/2021	Cowen	Boost Price Target	Outperform	$186.00 ➝ $210.00	Low	i
11/18/2020	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		Low	i
11/13/2020	Mizuho	Boost Price Target	Neutral	$150.00 ➝ $178.00	Medium	i
11/5/2020	Credit Suisse Group	Boost Price Target	Neutral	$174.00 ➝ $178.00	Medium	i
11/4/2020	Morgan Stanley	Boost Price Target	Overweight	$204.00 ➝ $219.00	High	i
11/4/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$202.00 ➝ $222.00	High	i
11/2/2020	Barclays	Upgrade	Equal Weight ➝ Overweight	$166.00 ➝ $166.00	Medium	i
8/4/2020	JPMorgan Chase & Co.	Boost Price Target	Positive ➝ Overweight	$187.00 ➝ $198.00	Low	i
8/4/2020	Credit Suisse Group	Boost Price Target	Neutral	$160.00 ➝ $162.00	Low	i Rating by Jailendra Singh at Credit Suisse Group AG
8/4/2020	Morgan Stanley	Boost Price Target	Overweight	$194.00 ➝ $204.00	Medium	i Rating by Ricky Goldwasser at Morgan Stanley
8/4/2020	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$169.00 ➝ $202.00	Medium	i
7/8/2020	Guggenheim	Boost Price Target	Buy	$168.00 ➝ $175.00	Medium	i Rating by Glen Santangelo at Guggenheim
6/15/2020	Morgan Stanley	Boost Price Target	Overweight	$163.00 ➝ $194.00	Medium	i Rating by Ricky Goldwasser at Morgan Stanley
5/27/2020	Guggenheim	Boost Price Target	Buy	$147.00 ➝ $168.00	High	i Rating by Glen Santangelo at Guggenheim
5/26/2020	UBS Group	Boost Price Target	Buy	$160.00 ➝ $165.00	Low	i Rating by Kevin Caliendo at UBS Group AG
5/22/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$184.00	Low	i
5/22/2020	Morgan Stanley	Boost Price Target	Overweight	$150.00 ➝ $163.00	Low	i Rating by Ricky Goldwasser at Morgan Stanley
5/21/2020	Cowen	Boost Price Target	Outperform	$174.00 ➝ $186.00	Low	i
5/21/2020	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold	$173.00 ➝ $169.00	Low	i
5/21/2020	Mizuho	Boost Price Target	Neutral	$140.00 ➝ $147.00	Low	i
5/20/2020	Cfra	Lower Price Target	Buy	$179.00 ➝ $171.00	Medium	i
5/15/2020	UBS Group	Upgrade	Neutral ➝ Buy	$151.00 ➝ $160.00	High	i Rating by Steven Strycula at UBS Group AG
4/22/2020	Credit Suisse Group	Initiated Coverage	Neutral	$146.00	Low	i
4/2/2020	Credit Suisse Group	Lower Price Target	Neutral	$155.00 ➝ $147.00	High	i
3/31/2020	Barclays	Lower Price Target	Equal Weight	$170.00 ➝ $163.00	Medium	i
3/27/2020	Morgan Stanley	Lower Price Target	Overweight	$182.00 ➝ $150.00	Low	i Rating by Ricky Goldwasser at Morgan Stanley
3/18/2020	Credit Suisse Group	Reiterated Rating	Hold	$145.00	Medium	i
3/18/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$186.00 ➝ $187.00	High	i
3/18/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$173.00 ➝ $174.00	High	i
3/13/2020	Guggenheim	Upgrade	Neutral ➝ Buy		Medium	i
3/6/2020	Morgan Stanley	Reiterated Rating	Buy	$182.00	Medium	i Rating by Ricky Goldwasser at Morgan Stanley
2/11/2020	Morgan Stanley	Boost Price Target	Overweight	$168.00 ➝ $182.00	Medium	i Rating by Ricky Goldwasser at Morgan Stanley
2/7/2020	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$164.00 ➝ $197.00	Medium	i
2/5/2020	Robert W. Baird	Boost Price Target	Neutral	$161.00 ➝ $164.00	Medium	i
2/5/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold	$153.00 ➝ $173.00	Medium	i
2/5/2020	Morgan Stanley	Boost Price Target	Overweight	$162.00 ➝ $168.00	Medium	i Rating by Ricky Goldwasser at Morgan Stanley
1/19/2020	Barclays	Reiterated Rating	Hold	$170.00	Low	i
1/15/2020	Mizuho	Boost Price Target	Neutral	$137.00 ➝ $140.00	High	i
1/10/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$135.00 ➝ $162.00	Medium	i
1/9/2020	UBS Group	Downgrade	Sell	$147.00	High	i Rating by Steven Strycula at UBS Group AG
9/12/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$155.00	Medium	i
9/5/2019	Cleveland Research	Reiterated Rating	Hold		Low	i Rating by Rob Eich at Cleveland Research
8/27/2019	Morgan Stanley	Boost Price Target	Equal Weight	$130.00 ➝ $135.00	High	i
8/5/2019	Wolfe Research	Downgrade	Outperform ➝ Peer Perform		Low	i
7/31/2019	Bank of America	Set Price Target	Buy	$160.00	N/A	i Rating by Michael Cherny at Bank of America Co.
7/22/2019	Credit Suisse Group	Initiated Coverage	Neutral	$143.00	Low	i
7/22/2019	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$152.00	Low	i
7/22/2019	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$164.00	Low	i
4/2/2019	Wolfe Research	Initiated Coverage	Outperform		High	i
2/1/2019	Barclays	Reiterated Rating	Hold	$130.00	Medium	i
1/25/2019	Deutsche Bank Aktiengesellschaft	Upgrade	Sell ➝ Hold	$175.00	Low	i
1/17/2019	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$134.00	Low	i
1/6/2019	Barclays	Reiterated Rating	Hold	$124.00	Low	i
12/9/2018	Morgan Stanley	Lower Price Target		$142.00 ➝ $130.00	Low	i Rating by Ricky Goldwasser at Morgan Stanley
12/3/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$142.00 ➝ $130.00	Medium	i
10/26/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$150.00 ➝ $136.00	High	i
10/26/2018	Royal Bank of Canada	Set Price Target	Hold	$155.00	Medium	i Rating by George Hill at Royal Bank of Canada
8/12/2018	Mizuho	Reiterated Rating	Hold	$133.00	High	i
7/27/2018	JPMorgan Chase & Co.	Lower Price Target	Overweight ➝ Overweight	$181.00 ➝ $160.00	Low	i
7/27/2018	Jefferies Financial Group	Reiterated Rating	Buy	$160.00	Medium	i
7/27/2018	Royal Bank of Canada	Reiterated Rating	Hold	$152.00	Medium	i Rating by George Hill at Royal Bank of Canada
7/20/2018	Robert W. Baird	Downgrade	Outperform ➝ Neutral		Low	i
7/20/2018	Citigroup	Lower Price Target	Buy	$160.00 ➝ $2.86	Low	i
7/10/2018	Standpoint Research	Upgrade	Hold ➝ Buy		Low	i
7/3/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$175.00 ➝ $142.00	Low	i
6/29/2018	Royal Bank of Canada	Lower Price Target	Market Perform	$158.00	High	i
5/29/2018	SVB Leerink	Set Price Target	Market Perform ➝ Market Perform	$170.00 ➝ $160.00	High	i Rating by David Larsen at SVB Leerink LLC
4/11/2018	Bank of America	Lower Price Target	Buy ➝ Buy	$179.00 ➝ $172.00	Low	i Rating by Michael Cherny at Bank of America Co.
3/8/2018	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$165.00	Medium	i
2/27/2018	Bank of America	Initiated Coverage	Buy ➝ Buy	$179.00	Low	i
2/2/2018	Credit Suisse Group	Reiterated Rating	Sell	$130.00	High	i
2/2/2018	Mizuho	Lower Price Target	Neutral ➝ Neutral	$186.00 ➝ $179.00	High	i Rating by Ann Hynes at Mizuho
1/24/2018	Mizuho	Set Price Target	Hold	$186.00	Low	i Rating by Ann Hynes at Mizuho
1/24/2018	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$205.00	High	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
1/23/2018	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $180.00	Medium	i Rating by Kevin Caliendo at Needham & Company LLC
1/17/2018	Robert W. Baird	Reiterated Rating	Buy	$200.00	Low	i
1/4/2018	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$179.00	Low	i
12/4/2017	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$175.00	High	i
11/9/2017	Credit Suisse Group	Reiterated Rating	Underperform	$155.00 ➝ $130.00	N/A	i
11/1/2017	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$178.00 ➝ $173.00	N/A	i Rating by Kevin Caliendo at Needham & Company LLC
10/27/2017	Royal Bank of Canada	Reiterated Rating	Hold	$170.00	N/A	i
10/24/2017	Mizuho	Set Price Target	Hold	$168.00	N/A	i Rating by Ann Hynes at Mizuho
10/24/2017	Needham & Company LLC	Set Price Target	Buy	$179.00 ➝ $178.00	N/A	i Rating by Kevin Caliendo at Needham & Company LLC
10/18/2017	Jefferies Financial Group	Set Price Target	Hold	$165.00	N/A	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
10/16/2017	Needham & Company LLC	Set Price Target	Buy	$179.00	N/A	i Rating by Kevin Caliendo at Needham & Company LLC
10/10/2017	Cowen	Upgrade	Market Perform ➝ Outperform	$176.00 ➝ $189.00	N/A	i
9/19/2017	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform	$168.00	Low	i
9/19/2017	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$175.00 ➝ $178.00	Low	i
9/14/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$184.00 ➝ $172.00	High	i
9/8/2017	Needham & Company LLC	Upgrade	Hold ➝ Buy	$179.00	Low	i
8/29/2017	Jefferies Financial Group	Set Price Target	Hold	$165.00	Low	i Rating by Brian Tanquilut at Jefferies Financial Group Inc.
7/27/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$153.00	Low	i
6/29/2017	SVB Leerink	Boost Price Target	Market Perform	$170.00	Medium	i Rating by David Larsen at SVB Leerink LLC
6/26/2017	UBS Group	Reiterated Rating	Neutral	$156.00 ➝ $166.00	N/A	i
6/4/2017	Barclays	Set Price Target	Buy	$187.00	Low	i Rating by Eric Percher at Barclays PLC
5/30/2017	Mizuho	Boost Price Target	Neutral ➝ Neutral	$147.00 ➝ $168.00	Low	i
5/25/2017	Morgan Stanley	Boost Price Target	Overweight	$165.00 ➝ $179.00	Low	i
5/23/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$189.00	Medium	i
5/19/2017	SVB Leerink	Set Price Target	Hold	$140.00	High	i Rating by David Larsen at SVB Leerink LLC
5/19/2017	UBS Group	Boost Price Target	Neutral ➝ Neutral	$145.00 ➝ $156.00	N/A	i
5/17/2017	Jefferies Financial Group	Initiated Coverage	Hold ➝ Hold	$153.00	Medium	i
4/27/2017	Barclays	Reiterated Rating	Overweight	$174.00	Low	i
4/21/2017	SVB Leerink	Reiterated Rating	Hold	$140.00	Low	i Rating by David Larsen at SVB Leerink LLC
4/17/2017	Evercore ISI	Reiterated Rating	Outperform	$166.00	Low	i
4/4/2017	Needham & Company LLC	Initiated Coverage	Hold		Low	i
3/6/2017	Citigroup	Boost Price Target	Buy	$169.00 ➝ $175.00	N/A	i
3/3/2017	Credit Suisse Group	Reiterated Rating	Sell		N/A	i
1/21/2017	SVB Leerink	Set Price Target	Hold	$155.00	N/A	i Rating by David Larsen at SVB Leerink LLC
1/18/2017	Avondale Partners	Upgrade	Market Perform ➝ Outperform	$157.00 ➝ $193.00	N/A	i Rating by G. Bolan at Avondale Partners
1/5/2017	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$171.00 ➝ $169.00	N/A	i
1/3/2017	Mizuho	Downgrade	Buy ➝ Neutral	$147.00	N/A	i
11/23/2016	Credit Suisse Group	Downgrade	Neutral ➝ Underperform	$150.00 ➝ $131.00	N/A	i
11/11/2016	Standpoint Research	Downgrade	Buy ➝ Hold		N/A	i
11/9/2016	Mizuho	Upgrade	Neutral ➝ Buy	$147.00	N/A	i Rating by Ann Hynes at Mizuho
10/28/2016	Standpoint Research	Upgrade	Hold ➝ Buy	$156.00	N/A	i
10/28/2016	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$196.00 ➝ $153.00	N/A	i
10/28/2016	SVB Leerink	Downgrade	Outperform ➝ Market Perform		N/A	i Rating by D. Larsen at SVB Leerink LLC
10/28/2016	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$200.00 ➝ $164.00	N/A	i Rating by Eric Coldwell at Robert W. Baird
10/5/2016	UBS Group	Initiated Coverage	Neutral	$182.00	N/A	i
9/26/2016	Mizuho	Lower Price Target	Neutral	$197.00 ➝ $183.00	N/A	i Rating by Ann Hynes at Mizuho
9/19/2016	Argus	Reiterated Rating	Hold		N/A	i
9/16/2016	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$210.00 ➝ $189.00	N/A	i
9/1/2016	SVB Leerink	Reiterated Rating	Outperform	$230.00	N/A	i
8/11/2016	Mizuho	Boost Price Target	Neutral	$174.00 ➝ $197.00	N/A	i Rating by Ann Hynes at Mizuho
8/9/2016	JPMorgan Chase & Co.	Boost Price Target	Overweight	$210.00 ➝ $221.00	N/A	i Rating by Lisa Gill at JPMorgan Chase & Co.
7/28/2016	Morgan Stanley	Boost Price Target	Overweight	$199.00 ➝ $211.00	N/A	i Rating by Ricky Goldwasser at Morgan Stanley
7/28/2016	Citigroup	Boost Price Target	Buy	$215.00 ➝ $225.00	N/A	i
7/18/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A	i Rating by George Hill at Deutsche Bank Aktiengesellschaft
7/6/2016	Avondale Partners	Reiterated Rating	Market Perform	$172.00 ➝ $197.00	N/A	i
6/30/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Lisa Gill at JPMorgan Chase & Co.
6/30/2016	Bank of America	Reiterated Rating	Hold		N/A	i Rating by Steven Valiquette at Bank of America Co.
6/29/2016	Robert W. Baird	Reiterated Rating	Buy	$220.00	N/A	i Rating by Eric Coldwell at Robert W. Baird
6/29/2016	(FBRC)	Reiterated Rating	Buy	$210.00	N/A	i Rating by Steven Halper at (FBRC)
6/22/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Steven Halper at (FBRC)
6/8/2016	Bank of America	Initiated Coverage	Hold		N/A	i Rating by Steven Valiquette at Bank of America Co.
6/7/2016	Bank of America	Reiterated Rating	Neutral	$190.00	N/A	i
6/7/2016	Mizuho	Reiterated Rating	Neutral	$164.00 ➝ $174.00	N/A	i Rating by Ann Hynes at Mizuho
6/4/2016	(FBRC)	Reiterated Rating	Buy		N/A	i Rating by Steven Halper at (FBRC)
6/1/2016	Raymond James	Downgrade	Strong-Buy ➝ Outperform		N/A	i
5/31/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i Rating by Ricky Goldwasser at Morgan Stanley
5/16/2016	Credit Suisse Group	Reiterated Rating	Hold		N/A	i Rating by Robert Willoughby at Credit Suisse Group AG
5/5/2016	SVB Leerink	Reiterated Rating	Buy	$200.00	N/A	i
5/5/2016	Avondale Partners	Downgrade	Outperform ➝ Market Perform	$203.00 ➝ $172.00	N/A	i Rating by G. Bolan at Avondale Partners
4/26/2016	Standpoint Research	Downgrade	Buy ➝ Hold		N/A	i
4/18/2016	Avondale Partners	Initiated Coverage	Outperform	$203.00	N/A	i
4/15/2016	The Goldman Sachs Group	Reiterated Rating	Buy	$188.00	N/A	i
4/12/2016	UBS Group	Reiterated Rating	Buy		N/A	i
3/17/2016	(FBRC)	Reiterated Rating	Outperform		N/A	i Rating by Steven Halper at (FBRC)
3/16/2016	Deutsche Bank Aktiengesellschaft	Reiterated Rating	Buy		N/A	i Rating by George Hill at Deutsche Bank Aktiengesellschaft
3/15/2016	Credit Suisse Group	Initiated Coverage	Neutral	$175.00	N/A	i
3/15/2016	Cowen	Downgrade	Outperform ➝ Market Perform	$208.00 ➝ $173.00	N/A	i
3/11/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by David Francis at Royal Bank of Canada

(Data available from 3/7/2016 forward)

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and solutions for life sciences companies, including offering multiple distribution channels and clinical trial access to specific patient populations through its network of oncology physicians. The segment also sells financial, operational and clinical solutions to pharmacies; and offers consulting, outsourcing, and other services. The Prescription Technology Solutions segment operates in the healthcare delivery system to connect pharmacies, providers, payers, and biopharma for next-generation patient access and adherence solutions. The International segment provides drug distribution services, specialty pharmacy, and retail and infusion care services. The Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Today's Range

Now: $175.11

$169.75

$175.78

50 Day Range

MA: $180.04

$169.52

$186.07

52 Week Range

Now: $175.11

$112.60

$187.67

Volume

880,366 shs

Average Volume

1,079,969 shs

Market Capitalization

$27.87 billion

P/E Ratio

13.33

Dividend Yield

0.98%

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of McKesson?

The following Wall Street analysts have issued stock ratings on McKesson in the last twelve months: Barclays PLC, Cfra, Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for MCK.

What is the current price target for McKesson?

12 Wall Street analysts have set twelve-month price targets for McKesson in the last year. Their average twelve-month price target is $191.33, suggesting a possible upside of 9.3%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting MCK will reach $231.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $165.00 for McKesson in the next year.
View the latest price targets for MCK.

What is the current consensus analyst rating for McKesson?

McKesson currently has 2 hold ratings, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MCK will outperform the market and that investors should add to their positions of McKesson.
View the latest ratings for MCK.

What other companies compete with McKesson?

Other companies that are similar to McKesson include AmerisourceBergen, Cardinal Health, Henry Schein, Patterson Companies and Owens & Minor.

How do I contact McKesson's investor relations team?

McKesson's physical mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company's listed phone number is 972-446-4800 and its investor relations email address is inves[email protected] The official website for McKesson is www.mckesson.com.

NYSE:MCK - McKesson Stock Price Target and Predictions

Analyst Price Target for MCK

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of McKesson?

What is the current price target for McKesson?

What is the current consensus analyst rating for McKesson?

What other companies compete with McKesson?

How do I contact McKesson's investor relations team?